{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-24-000033","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.301741+00:00","generated_at":"2026-05-28T23:20:32.280093+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Serina sells UniverXome subsidiary to Juvenescence affiliate for $10 plus assumption of ~$11.2M debt","bullets":["Sold UniverXome (holding ReCyte and Reverse Bio) to JuvVentures for $10 and assumption of ~$11.2M secured debt.","Juvenescence is Serina's largest shareholder; Special Committee approved with third-party valuation.","UniverXome owned 94.8% of ReCyte and 100% of Reverse Bio, legacy AgeX assets from pre-merger.","Intellectual property transfer not perfected; buyer bears future filing costs.","Company makes no warranty beyond express representations; assets fully encumbered by pre-existing debt to buyer."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-24-000033","json":"https://secwatch.observer/filing/0001708599-24-000033.json","markdown":"https://secwatch.observer/filing/0001708599-24-000033.md","text":"https://secwatch.observer/filing/0001708599-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/0001708599-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/ser-20241223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:20:32.280093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0af7118cd9b9bf603e1f37d2fcbf259efdc44bb","claim":"Serina Therapeutics, Inc. completed a disposition involving JuvVentures (UK) Limited for assumed approximately $11.2 million of secured debt (closed 2024-12-23).","evidence_excerpt":"with the intent to revert aged or diseased cells to a healthy and functional state. As consideration for the purchase of UniverXome, Juvenescence assumed approximately $11.2 million of secured debt owed by UniverXome to Juvenescence in addition to a nominal cash payment. The debt assumed by Juvenescence was secured by substantially all of the assets of","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/0001708599-24-000033-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"JuvVentures (UK) Limited"},{"label":"Consideration","value":"assumed approximately $11.2 million of secured debt"},{"label":"Closing","value":"2024-12-23"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}